Table 4 New chemical entities (NCEs) approved between 1975 and 1999 by drug class and relative to disease burden and drug sales [9]
From: Developing countries and neglected diseases: challenges and perspectives
Therapeutic areas | Approved NCEs 1975–1999 | Proportion of worldwide sales Year 1999 | NCEs by DALY | Drug sales (millions of US$) by DALY |
|---|---|---|---|---|
Central nervous system | 211 (15·1%) | 15·1% | 1·32 | 193 |
Cardiovascular | 179 (12·8%) | 19·8% | 1·25 | 283 |
Cytostatics (neoplasms) | 111 (8·0%) | 3·7% | 1·31 | 90 |
Respiratory (non-infectious) | 89 (6·4%) | 9·3% | 1·44 | 307 |
Anti-infectives and antiparasitics | 224 (16·1%) | 10·3% | 0·55 | 52 |
HIV/AIDS | 26 (1·9%) | 1·5% | 0·37 | 44 |
Tuberculosis | 3 (0·2%) | 0·2% | 0·11 | 11 |
Tropical diseases (Total) | 13 (0·9%) | 0·2% | 0·10 | 3 |
Malaria | 4 (0·3%) | 0·1% | 0·10 | 5 |
Other therapeutic categories | 579 (41·6%) | 41·9% | 1·10 | 163 |
Total | 1393 (100%) | 100% | 1·01 | 148 |